25 XP   0   0   10

Impel Neuropharma Inc
Buy, Hold or Sell?

Let's analyse Impel Neuropharma Inc together

PenkeI guess you are interested in Impel Neuropharma Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Impel Neuropharma Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Impel Neuropharma Inc

I send you an email if I find something interesting about Impel Neuropharma Inc.

Quick analysis of Impel Neuropharma Inc (30 sec.)










What can you expect buying and holding a share of Impel Neuropharma Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
8.3%

What is your share worth?

Current worth
$-3.85
Expected worth in 1 year
$-6.76
How sure are you?
16.7%

+ What do you gain per year?

Total Gains per Share
$-2.91
Return On Investment
-18,531.8%

For what price can you sell your share?

Current Price per Share
$0.02
Expected price per share
$0.011 - $0.0606
How sure are you?
50%

1. Valuation of Impel Neuropharma Inc (5 min.)




Live pricePrice per Share (EOD)

$0.02

2. Growth of Impel Neuropharma Inc (5 min.)




Is Impel Neuropharma Inc growing?

Current yearPrevious yearGrowGrow %
How rich?-$91.9m$15.4m-$87.4m-121.4%

How much money is Impel Neuropharma Inc making?

Current yearPrevious yearGrowGrow %
Making money-$24m-$31.5m$7.5m31.4%
Net Profit Margin-498.9%-2,110.4%--

How much money comes from the company's main activities?

3. Financial Health of Impel Neuropharma Inc (5 min.)




What can you expect buying and holding a share of Impel Neuropharma Inc? (5 min.)

Welcome investor! Impel Neuropharma Inc's management wants to use your money to grow the business. In return you get a share of Impel Neuropharma Inc.

What can you expect buying and holding a share of Impel Neuropharma Inc?

First you should know what it really means to hold a share of Impel Neuropharma Inc. And how you can make/lose money.

Speculation

The Price per Share of Impel Neuropharma Inc is $0.0157. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Impel Neuropharma Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Impel Neuropharma Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-3.85. Based on the TTM, the Book Value Change Per Share is $-0.73 per quarter. Based on the YOY, the Book Value Change Per Share is $-1.03 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Impel Neuropharma Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.58-3,681.5%-0.87-5,519.5%-1.13-7,196.5%-0.90-5,703.2%-0.90-5,703.2%
Usd Book Value Change Per Share-0.53-3,397.1%-0.73-4,638.2%-1.03-6,541.0%-0.32-2,041.1%-0.32-2,041.1%
Usd Dividend Per Share0.000.0%0.005.3%0.000.0%0.001.8%0.001.8%
Usd Total Gains Per Share-0.53-3,397.1%-0.73-4,633.0%-1.03-6,541.0%-0.32-2,039.3%-0.32-2,039.3%
Usd Price Per Share0.43-1.71-7.30-4.76-4.76-
Price to Earnings Ratio-0.19--0.60--1.66--1.28--1.28-
Price-to-Total Gains Ratio-0.81--2.73--7.20--2.68--2.68-
Price to Book Ratio-0.11--0.75-15.30-5.52-5.52-
Price-to-Total Gains Ratio-0.81--2.73--7.20--2.68--2.68-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.0157
Number of shares63694
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.73-0.32
Usd Total Gains Per Share-0.73-0.32
Gains per Quarter (63694 shares)-46,329.39-20,393.18
Gains per Year (63694 shares)-185,317.56-81,572.74
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1211-185528-18532870-81643-81583
2421-371056-370646140-163286-163156
3632-556584-555964211-244929-244729
4842-742112-741282281-326572-326302
51053-927640-926600351-408215-407875
61263-1113169-1111918421-489857-489448
71474-1298697-1297236491-571500-571021
81684-1484225-1482554561-653143-652594
91895-1669753-1667872632-734786-734167
102105-1855281-1853190702-816429-815740

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.012.00.00.0%0.012.00.00.0%0.012.00.00.0%
Book Value Change Per Share0.04.00.00.0%2.010.00.016.7%2.010.00.016.7%2.010.00.016.7%2.010.00.016.7%
Dividend per Share1.00.03.025.0%1.00.011.08.3%1.00.011.08.3%1.00.011.08.3%1.00.011.08.3%
Total Gains per Share0.04.00.00.0%2.010.00.016.7%2.010.00.016.7%2.010.00.016.7%2.010.00.016.7%

Fundamentals of Impel Neuropharma Inc

About Impel Neuropharma Inc

Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. The company was incorporated in 2008 and is headquartered in Seattle, Washington. On December 19, 2023, Impel Pharmaceuticals Inc, along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Northern District of Texas.

Fundamental data was last updated by Penke on 2024-03-20 21:01:06.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Impel Neuropharma Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Impel Neuropharma Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Impel Neuropharma Inc to the  industry mean.
  • A Net Profit Margin of -275.0% means that $-2.75 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Impel Neuropharma Inc:

  • The MRQ is -275.0%. The company is making a huge loss. -2
  • The TTM is -498.9%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-275.0%TTM-498.9%+223.8%
TTM-498.9%YOY-2,110.4%+1,611.5%
TTM-498.9%5Y-3,161.0%+2,662.2%
5Y-3,161.0%10Y-3,161.0%0.0%
1.1.2. Return on Assets

Shows how efficient Impel Neuropharma Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Impel Neuropharma Inc to the  industry mean.
  • -39.4% Return on Assets means that Impel Neuropharma Inc generated $-0.39 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Impel Neuropharma Inc:

  • The MRQ is -39.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -39.1%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-39.4%TTM-39.1%-0.3%
TTM-39.1%YOY-27.4%-11.7%
TTM-39.1%5Y-43.7%+4.5%
5Y-43.7%10Y-43.7%0.0%
1.1.3. Return on Equity

Shows how efficient Impel Neuropharma Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Impel Neuropharma Inc to the  industry mean.
  • 0.0% Return on Equity means Impel Neuropharma Inc generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Impel Neuropharma Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-228.3%+228.3%
TTM-5Y-81.4%+81.4%
5Y-81.4%10Y-81.4%0.0%

1.2. Operating Efficiency of Impel Neuropharma Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Impel Neuropharma Inc is operating .

  • Measures how much profit Impel Neuropharma Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Impel Neuropharma Inc to the  industry mean.
  • An Operating Margin of -267.7% means the company generated $-2.68  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Impel Neuropharma Inc:

  • The MRQ is -267.7%. The company is operating very inefficient. -2
  • The TTM is -351.7%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-267.7%TTM-351.7%+84.0%
TTM-351.7%YOY-1,749.2%+1,397.5%
TTM-351.7%5Y-2,753.9%+2,402.3%
5Y-2,753.9%10Y-2,753.9%0.0%
1.2.2. Operating Ratio

Measures how efficient Impel Neuropharma Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to  industry mean).
  • An Operation Ratio of 3.55 means that the operating costs are $3.55 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Impel Neuropharma Inc:

  • The MRQ is 3.550. The company is inefficient in keeping operating costs low. -1
  • The TTM is 4.472. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ3.550TTM4.472-0.922
TTM4.472YOY18.332-13.860
TTM4.4725Y28.221-23.749
5Y28.22110Y28.2210.000

1.3. Liquidity of Impel Neuropharma Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Impel Neuropharma Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to  industry mean).
  • A Current Ratio of 0.19 means the company has $0.19 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Impel Neuropharma Inc:

  • The MRQ is 0.188. The company is unable to pay all its short-term debts. -2
  • The TTM is 1.597. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ0.188TTM1.597-1.409
TTM1.597YOY5.771-4.174
TTM1.5975Y3.770-2.173
5Y3.77010Y3.7700.000
1.3.2. Quick Ratio

Measures if Impel Neuropharma Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Impel Neuropharma Inc to the  industry mean.
  • A Quick Ratio of 0.05 means the company can pay off $0.05 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Impel Neuropharma Inc:

  • The MRQ is 0.055. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 1.296. The company is able to pay all its short-term debts with the most liquid assets. +1
Trends
Current periodCompared to+/- 
MRQ0.055TTM1.296-1.241
TTM1.296YOY5.276-3.980
TTM1.2965Y3.417-2.121
5Y3.41710Y3.4170.000

1.4. Solvency of Impel Neuropharma Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Impel Neuropharma Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Impel Neuropharma Inc to industry mean.
  • A Debt to Asset Ratio of 3.62 means that Impel Neuropharma Inc assets are financed with 362.0% credit (debt) and the remaining percentage (100% - 362.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Impel Neuropharma Inc:

  • The MRQ is 3.620. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 2.503. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ3.620TTM2.503+1.117
TTM2.503YOY0.864+1.639
TTM2.5035Y3.313-0.810
5Y3.31310Y3.3130.000
1.4.2. Debt to Equity Ratio

Measures if Impel Neuropharma Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Impel Neuropharma Inc to the  industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Impel Neuropharma Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY8.761-8.761
TTM-5Y2.999-2.999
5Y2.99910Y2.9990.000

2. Market Valuation of Impel Neuropharma Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Impel Neuropharma Inc generates.

  • Above 15 is considered overpriced but always compare Impel Neuropharma Inc to the  industry mean.
  • A PE ratio of -0.19 means the investor is paying $-0.19 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Impel Neuropharma Inc:

  • The EOD is -0.007. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.186. Based on the earnings, the company is expensive. -2
  • The TTM is -0.602. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.007MRQ-0.186+0.179
MRQ-0.186TTM-0.602+0.416
TTM-0.602YOY-1.660+1.059
TTM-0.6025Y-1.281+0.679
5Y-1.28110Y-1.2810.000
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Impel Neuropharma Inc:

  • The EOD is -0.005. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.147. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.508. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.005MRQ-0.147+0.142
MRQ-0.147TTM-0.508+0.361
TTM-0.508YOY-1.744+1.236
TTM-0.5085Y-1.373+0.865
5Y-1.37310Y-1.3730.000
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Impel Neuropharma Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to industry mean).
  • A PB ratio of -0.11 means the investor is paying $-0.11 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Impel Neuropharma Inc:

  • The EOD is -0.004. Based on the equity, the company is expensive. -2
  • The MRQ is -0.112. Based on the equity, the company is expensive. -2
  • The TTM is -0.746. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.004MRQ-0.112+0.108
MRQ-0.112TTM-0.746+0.634
TTM-0.746YOY15.304-16.050
TTM-0.7465Y5.516-6.262
5Y5.51610Y5.5160.000
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Impel Neuropharma Inc.

3.1. Institutions holding Impel Neuropharma Inc

Institutions are holding 71.619% of the shares of Impel Neuropharma Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31venBio Partners LLC11.54720.0511275979100
2023-12-31St Germain D J Co Inc0.00630150000
2023-09-30Royal Bank of Canada0.0005010900
2023-12-31Vivo Capital, LLC000-2884789-100
2023-12-31CapTrust Financial Advisors000-14407-100
2023-12-31State Street Corporation000-25200-100
2023-12-315AM Venture Management, LLC000-2884791-100
2023-12-31Wells Fargo & Co000-57-100
2023-12-31Tower Research Capital LLC000-7936-100
2023-12-31Northern Trust Corp000-13218-100
2023-09-30LAURION CAPITAL MANAGEMENT LP000-124800-100
2023-09-30Bridgeway Capital Management, LLC000-63300-100
2023-12-31Millennium Management LLC000-21485-100
2023-12-31Brighton Jones LLC000-14145-100
2023-12-31Morgan Stanley - Brokerage Accounts000-2000-100
2023-12-31Lindbrook Capital, LLC000-3056-100
2023-12-31Raymond James & Associates000-14500-100
2023-12-31Kohlberg Kravis Roberts & Co LP000-4135971-100
2023-12-31DCF Advisers, LLC000-178500-100
2023-12-31Virtu Financial LLC000-16112-100
Total 11.5540.05112761400-10404267-376.8%

3.2. Funds holding Impel Neuropharma Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-10-31Vanguard Instl Ttl Stck Mkt Idx Tr0.0514012285-384524-96.9041
2024-01-31BlackRock Advantage SMID Cap V.I. Fd I0.0110.0001262100
2024-02-29LUX IM Global Medtech HX0.00530127000
2023-09-30BlackRock Extended Mkt Composite0.0015034700
Total 0.06920.000116523-384524-2,327.2%

3.3. Insider Transactions

Insiders are holding 0.523% of the shares of Impel Neuropharma Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-12-18Vivo Capital Viii, LlcSELL2377110.11
2023-12-15Vivo Capital Viii, LlcSELL1000000.29

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Impel Neuropharma Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.533-0.728+37%-1.027+93%-0.320-40%-0.320-40%
Book Value Per Share---3.845-3.014-22%0.644-697%-1.315-66%-1.315-66%
Current Ratio--0.1881.597-88%5.771-97%3.770-95%3.770-95%
Debt To Asset Ratio--3.6202.503+45%0.864+319%3.313+9%3.313+9%
Debt To Equity Ratio----0%8.761-100%2.999-100%2.999-100%
Dividend Per Share---0.001-100%-0%0.000-100%0.000-100%
Eps---0.578-0.867+50%-1.130+95%-0.895+55%-0.895+55%
Free Cash Flow Per Share---0.731-0.857+17%-1.039+42%-0.823+12%-0.823+12%
Free Cash Flow To Equity Per Share---0.436-0.784+80%-0.330-24%-0.012-97%-0.012-97%
Gross Profit Margin--1.0001.418-29%1.009-1%1.142-12%1.142-12%
Market Cap375230.000-2639%10277000.00040928750.000-75%174410250.000-94%113664416.667-91%113664416.667-91%
Net Profit Margin---2.750-4.989+81%-21.104+667%-31.610+1049%-31.610+1049%
Operating Margin---2.677-3.517+31%-17.492+553%-27.539+929%-27.539+929%
Operating Ratio--3.5504.472-21%18.332-81%28.221-87%28.221-87%
Pb Ratio-0.004+96%-0.112-0.746+567%15.304-101%5.516-102%5.516-102%
Pe Ratio-0.007+96%-0.186-0.602+223%-1.660+793%-1.281+589%-1.281+589%
Price Per Share0.016-2639%0.4301.713-75%7.298-94%4.756-91%4.756-91%
Price To Free Cash Flow Ratio-0.005+96%-0.147-0.508+246%-1.744+1087%-1.373+834%-1.373+834%
Price To Total Gains Ratio-0.029+96%-0.806-2.734+239%-7.200+793%-2.682+233%-2.682+233%
Quick Ratio--0.0551.296-96%5.276-99%3.417-98%3.417-98%
Return On Assets---0.394-0.391-1%-0.274-30%-0.437+11%-0.437+11%
Return On Equity----0%-2.2830%-0.8140%-0.8140%
Total Gains Per Share---0.533-0.727+36%-1.027+93%-0.320-40%-0.320-40%
Usd Book Value---91905000.000-72031250.000-22%15402750.000-697%-31436583.333-66%-31436583.333-66%
Usd Book Value Change Per Share---0.533-0.728+37%-1.027+93%-0.320-40%-0.320-40%
Usd Book Value Per Share---3.845-3.014-22%0.644-697%-1.315-66%-1.315-66%
Usd Dividend Per Share---0.001-100%-0%0.000-100%0.000-100%
Usd Eps---0.578-0.867+50%-1.130+95%-0.895+55%-0.895+55%
Usd Free Cash Flow---17481000.000-20494000.000+17%-24839750.000+42%-19662833.333+12%-19662833.333+12%
Usd Free Cash Flow Per Share---0.731-0.857+17%-1.039+42%-0.823+12%-0.823+12%
Usd Free Cash Flow To Equity Per Share---0.436-0.784+80%-0.330-24%-0.012-97%-0.012-97%
Usd Market Cap375230.000-2639%10277000.00040928750.000-75%174410250.000-94%113664416.667-91%113664416.667-91%
Usd Price Per Share0.016-2639%0.4301.713-75%7.298-94%4.756-91%4.756-91%
Usd Profit---13814000.000-24028500.000+74%-31585250.000+129%-24022750.000+74%-24022750.000+74%
Usd Revenue--5023000.0005246750.000-4%2055250.000+144%2441583.333+106%2441583.333+106%
Usd Total Gains Per Share---0.533-0.727+36%-1.027+93%-0.320-40%-0.320-40%
 EOD+2 -6MRQTTM+17 -17YOY+18 -155Y+15 -2010Y+15 -20

4.2. Fundamental Score

Let's check the fundamental score of Impel Neuropharma Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.007
Price to Book Ratio (EOD)Between0-1-0.004
Net Profit Margin (MRQ)Greater than0-2.750
Operating Margin (MRQ)Greater than0-2.677
Quick Ratio (MRQ)Greater than10.055
Current Ratio (MRQ)Greater than10.188
Debt to Asset Ratio (MRQ)Less than13.620
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.394
Total1/10 (10.0%)

4.3. Technical Score

Let's check the technical score of Impel Neuropharma Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5036.397
Ma 20Greater thanMa 500.026
Ma 50Greater thanMa 1000.115
Ma 100Greater thanMa 2000.243
OpenGreater thanClose0.020
Total1/5 (20.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-09-302022-12-312023-03-312023-06-302023-09-30
Income Tax Expense  9,8573,41413,271-4,7078,564-5,4923,072-3,707-635



Latest Balance Sheet

Balance Sheet of 2023-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets35,073
Total Liabilities126,978
Total Stockholder Equity-91,905
 As reported
Total Liabilities 126,978
Total Stockholder Equity+ -91,905
Total Assets = 35,073

Assets

Total Assets35,073
Total Current Assets23,427
Long-term Assets11,646
Total Current Assets
Cash And Cash Equivalents 239
Net Receivables 6,592
Inventory 6,864
Other Current Assets 621
Total Current Assets  (as reported)23,427
Total Current Assets  (calculated)14,316
+/- 9,111
Long-term Assets
Property Plant Equipment 7,817
Long-term Assets Other 3,829
Long-term Assets  (as reported)11,646
Long-term Assets  (calculated)11,646
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities124,743
Long-term Liabilities2,235
Total Stockholder Equity-91,905
Total Current Liabilities
Short-term Debt 112,563
Short Long Term Debt 111,001
Accounts payable 3,734
Other Current Liabilities 8,446
Total Current Liabilities  (as reported)124,743
Total Current Liabilities  (calculated)235,744
+/- 111,001
Long-term Liabilities
Capital Lease Obligations 3,797
Long-term Liabilities  (as reported)2,235
Long-term Liabilities  (calculated)3,797
+/- 1,562
Total Stockholder Equity
Common Stock24
Retained Earnings -372,348
Other Stockholders Equity 280,419
Total Stockholder Equity (as reported)-91,905
Total Stockholder Equity (calculated)-91,905
+/-0
Other
Capital Stock24
Cash and Short Term Investments 239
Common Stock Shares Outstanding 23,749
Liabilities and Stockholders Equity 35,073
Net Debt 114,559
Net Invested Capital 19,096
Net Working Capital -101,316
Property Plant and Equipment Gross 7,817
Short Long Term Debt Total 114,798



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-31
> Total Assets 
0
0
0
12,059
11,482
69,162
121,481
97,912
147,799
120,434
105,172
88,550
64,729
44,807
35,073
35,07344,80764,72988,550105,172120,434147,79997,912121,48169,16211,48212,059000
   > Total Current Assets 
0
0
0
8,172
6,259
65,567
118,203
94,576
142,184
114,432
99,276
79,809
51,884
32,904
23,427
23,42732,90451,88479,80999,276114,432142,18494,576118,20365,5676,2598,172000
       Cash And Cash Equivalents 
0
0
0
7,095
4,467
60,948
111,289
88,212
129,837
97,827
79,731
60,654
35,465
15,162
239
23915,16235,46560,65479,73197,827129,83788,212111,28960,9484,4677,095000
       Net Receivables 
0
0
0
229
229
25
1,274
1,352
3,909
4,818
6,129
7,444
6,280
6,814
6,592
6,5926,8146,2807,4446,1294,8183,9091,3521,27425229229000
       Other Current Assets 
0
0
0
848
1,563
4,594
4,385
2,188
2,942
4,882
4,794
3,284
2,125
418
621
6214182,1253,2844,7944,8822,9422,1884,3854,5941,563848000
   > Long-term Assets 
0
0
0
3,887
5,223
3,595
3,278
3,336
5,615
6,002
5,896
8,741
12,845
11,903
11,646
11,64611,90312,8458,7415,8966,0025,6153,3363,2783,5955,2233,887000
       Property Plant Equipment 
0
0
0
3,700
3,512
3,408
3,278
3,149
5,428
5,815
5,709
6,995
8,914
8,386
7,817
7,8178,3868,9146,9955,7095,8155,4283,1493,2783,4083,5123,700000
       Other Assets 
0
0
0
0
1,711
187
0
187
187
187
187
1,746
0
0
0
0001,74618718718718701871,7110000
> Total Liabilities 
0
0
0
145,559
155,891
17,864
45,595
45,404
120,317
116,524
127,461
132,707
137,634
123,965
126,978
126,978123,965137,634132,707127,461116,524120,31745,40445,59517,864155,891145,559000
   > Total Current Liabilities 
0
0
0
10,526
13,394
9,007
16,310
15,954
23,980
18,295
19,963
22,163
22,282
121,221
124,743
124,743121,22122,28222,16319,96318,29523,98015,95416,3109,00713,39410,526000
       Short-term Debt 
0
0
0
417
1,667
1,667
0
0
999
1,276
1,346
1,541
1,736
49,551
112,563
112,56349,5511,7361,5411,3461,276999001,6671,667417000
       Short Long Term Debt 
0
0
0
417
1,667
0
0
0
0
0
0
0
0
47,823
111,001
111,00147,823000000001,667417000
       Accounts payable 
0
0
0
4,314
6,425
5,461
8,700
6,367
8,995
4,747
4,751
6,092
6,133
3,458
3,734
3,7343,4586,1336,0924,7514,7478,9956,3678,7005,4616,4254,314000
       Other Current Liabilities 
0
0
0
2,622
2,677
3,546
7,610
9,587
13,986
12,272
13,866
14,530
14,413
68,212
8,446
8,44668,21214,41314,53013,86612,27213,9869,5877,6103,5462,6772,622000
   > Long-term Liabilities 
0
0
0
135,033
142,497
8,857
29,285
29,450
96,337
98,229
107,498
110,544
115,352
2,744
2,235
2,2352,744115,352110,544107,49898,22996,33729,45029,2858,857142,497135,033000
       Long term Debt Total 
0
0
0
0
0
8,857
29,285
29,450
0
0
0
0
0
0
0
000000029,45029,2858,85700000
       Warrants
0
0
0
0
127,168
0
0
0
0
0
0
0
0
0
0
0000000000127,1680000
       Other Liabilities 
0
0
0
0
0
0
0
0
405
0
1,890
0
0
0
0
00001,890040500000000
       Deferred Long Term Liability 
0
0
0
0
1,500
0
0
0
0
0
0
0
0
0
0
00000000001,5000000
> Total Stockholder Equity
0
0
0
-133,500
-144,409
51,298
75,886
52,508
27,482
3,910
-22,289
-44,157
-72,905
-79,158
-91,905
-91,905-79,158-72,905-44,157-22,2893,91027,48252,50875,88651,298-144,409-133,500000
   Common Stock
0
0
0
0
0
19
23
23
23
23
24
24
24
24
24
2424242424232323231900000
   Retained Earnings Total Equity
0
0
0
0
149,553
-165,035
-190,056
-214,798
0
0
0
0
0
0
0
0000000-214,798-190,056-165,035149,5530000
   Accumulated Other Comprehensive Income 00000000-120,563-69,16200000
   Capital Surplus 
0
0
0
0
5,144
216,314
265,919
267,283
0
0
0
0
0
0
0
0000000267,283265,919216,3145,1440000
   Treasury Stock000000000000000
   Other Stockholders Equity 
0
0
0
4,762
2,467
216,314
265,001
267,283
269,227
270,859
275,756
276,929
278,248
279,352
280,419
280,419279,352278,248276,929275,756270,859269,227267,283265,001216,3142,4674,762000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue20,987
Cost of Revenue-9,952
Gross Profit11,03511,035
 
Operating Income (+$)
Gross Profit11,035
Operating Expense-91,099
Operating Income-70,112-80,064
 
Operating Expense (+$)
Research Development4,156
Selling General Administrative76,991
Selling And Marketing Expenses-
Operating Expense91,09981,147
 
Net Interest Income (+$)
Interest Income-
Interest Expense--
Other Finance Cost-12,375
Net Interest Income-12,375
 
Pretax Income (+$)
Operating Income-70,112
Net Interest Income-12,375
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-74,279-78,320
EBIT - interestExpense = 0
-74,279
-74,279
Interest Expense-
Earnings Before Interest and Taxes (EBIT)--74,279
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-74,279
Tax Provision-0
Net Income From Continuing Ops-74,279-74,279
Net Income-74,279
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net8,20812,375
 

Technical Analysis of Impel Neuropharma Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Impel Neuropharma Inc. The general trend of Impel Neuropharma Inc is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Impel Neuropharma Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Impel Neuropharma Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.0212 < 0.0226 < 0.0606.

The bearish price targets are: 0.011 > 0.011 > 0.011.

Tweet this
Impel Neuropharma Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Impel Neuropharma Inc. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Impel Neuropharma Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Impel Neuropharma Inc. The current macd is -0.02890093.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Impel Neuropharma Inc price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Impel Neuropharma Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Impel Neuropharma Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Impel Neuropharma Inc Daily Moving Average Convergence/Divergence (MACD) ChartImpel Neuropharma Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Impel Neuropharma Inc. The current adx is 12.50.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Impel Neuropharma Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Impel Neuropharma Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Impel Neuropharma Inc. The current sar is 0.011.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Impel Neuropharma Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Impel Neuropharma Inc. The current rsi is 36.40. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Impel Neuropharma Inc Daily Relative Strength Index (RSI) ChartImpel Neuropharma Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Impel Neuropharma Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Impel Neuropharma Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Impel Neuropharma Inc Daily Stochastic Oscillator ChartImpel Neuropharma Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Impel Neuropharma Inc. The current cci is -53.66292944.

Impel Neuropharma Inc Daily Commodity Channel Index (CCI) ChartImpel Neuropharma Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Impel Neuropharma Inc. The current cmo is -28.45663265.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Impel Neuropharma Inc Daily Chande Momentum Oscillator (CMO) ChartImpel Neuropharma Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Impel Neuropharma Inc. The current willr is -92.03389831.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Impel Neuropharma Inc Daily Williams %R ChartImpel Neuropharma Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Impel Neuropharma Inc.

Impel Neuropharma Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Impel Neuropharma Inc. The current atr is 0.02556047.

Impel Neuropharma Inc Daily Average True Range (ATR) ChartImpel Neuropharma Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Impel Neuropharma Inc. The current obv is 113,670,140.

Impel Neuropharma Inc Daily On-Balance Volume (OBV) ChartImpel Neuropharma Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Impel Neuropharma Inc. The current mfi is 9.83378585.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Impel Neuropharma Inc Daily Money Flow Index (MFI) ChartImpel Neuropharma Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Impel Neuropharma Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-09-27STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-09-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-10-03DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-10-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-10-09DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-10-10STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-10-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-10-13STOCH LONG EXITThe %K line crosses below the %D line.
2023-10-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-10-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-10-23STOCH SHORT EXITThe %K line crosses above the %D line.
2023-10-24STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-10-26WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-10-30STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-03STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-06STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-07STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-09WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-11-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-16STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-11-21STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-11-22BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-27RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-30SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-04STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-08WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-13MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-14STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-20STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-12-22STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-26STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-05MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-08MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-12SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-17WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-26WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-31STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-02MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-05CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-09MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-12MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Impel Neuropharma Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Impel Neuropharma Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5036.397
Ma 20Greater thanMa 500.026
Ma 50Greater thanMa 1000.115
Ma 100Greater thanMa 2000.243
OpenGreater thanClose0.020
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Impel Neuropharma Inc with someone you think should read this too:
  • Are you bullish or bearish on Impel Neuropharma Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Impel Neuropharma Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Impel Neuropharma Inc

I send you an email if I find something interesting about Impel Neuropharma Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Impel Neuropharma Inc.

Receive notifications about Impel Neuropharma Inc in your mailbox!